AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Ultragenyx Pharmaceutical Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Sensei Biotherapeutics, Inc. (SNSE) announced, via an Item 3.01 Form 8-K, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Nasdaq Listing Qualifications Staff confirmed that SNSE’s common stock maintained a closing bid of at least $1.00 for ten consecutive business days (17 June â€� 1 July 2025). As a result, the prior deficiency notice has been closed and the threat of delisting has been removed.

This resolution eliminates near-term listing risk, restores eligibility for index inclusion and institutional ownership mandates tied to national exchange status, and reduces investor concern over potential liquidity constraints. However, compliance depends on SNSE’s ability to keep its share price above the threshold; any sustained drop below $1.00 could trigger a new notice. The filing contains no new operational or financial data and does not alter the company’s underlying fundamentals.

Sensei Biotherapeutics, Inc. (SNSE) ha annunciato, tramite un modulo 8-K, voce 3.01, di aver ripristinato la conformità con la Regola 5550(a)(2) del Nasdaq, che richiede un prezzo minimo di offerta di $1,00 per azione. Lo staff delle qualifiche di Nasdaq ha confermato che il prezzo di chiusura delle azioni ordinarie di SNSE è rimasto almeno a $1,00 per dieci giorni lavorativi consecutivi (dal 17 giugno al 1 luglio 2025). Di conseguenza, la precedente notifica di non conformità è stata chiusa e il rischio di esclusione dal listino è stato eliminato.

Questa risoluzione elimina il rischio di esclusione a breve termine, ripristina l’idoneità per l’inclusione negli indici e per i requisiti di proprietà istituzionale legati allo status di borsa nazionale, e riduce le preoccupazioni degli investitori riguardo a potenziali vincoli di liquidità. Tuttavia, la conformità dipende dalla capacità di SNSE di mantenere il prezzo delle azioni sopra la soglia; un calo prolungato sotto $1,00 potrebbe causare una nuova notifica. Il documento non contiene nuovi dati operativi o finanziari e non modifica i fondamentali dell’azienda.

Sensei Biotherapeutics, Inc. (SNSE) anunció, a través de un Formulario 8-K, ítem 3.01, que ha recuperado el cumplimiento con la Norma 5550(a)(2) del Nasdaq, que exige un precio mínimo de oferta de $1.00 por acción. El personal de calificaciones del Nasdaq confirmó que las acciones ordinarias de SNSE mantuvieron un precio de cierre de al menos $1.00 durante diez días hábiles consecutivos (del 17 de junio al 1 de julio de 2025). Como resultado, se cerró el aviso previo de incumplimiento y se eliminó la amenaza de exclusión de la lista.

Esta resolución elimina el riesgo de exclusión a corto plazo, restaura la elegibilidad para la inclusión en índices y los mandatos de propiedad institucional vinculados al estatus de bolsa nacional, y reduce la preocupación de los inversores sobre posibles restricciones de liquidez. Sin embargo, el cumplimiento depende de la capacidad de SNSE para mantener el precio de sus acciones por encima del umbral; cualquier caída sostenida por debajo de $1.00 podría desencadenar un nuevo aviso. La presentación no contiene nuevos datos operativos o financieros y no altera los fundamentos subyacentes de la empresa.

Sensei Biotherapeutics, Inc. (SNSE)ëŠ� 8-K ì–‘ì‹ì� 항목 3.01ì� 통해 나스ë‹� ìƒìž¥ 규칙 5550(a)(2) 준수를 회복했다ê³� 발표했습니다. ì� ê·œì¹™ì€ ì£¼ë‹¹ 최소 입찰가가 $1.00 ì´ìƒì´ì–´ì•� í•¨ì„ ìš”êµ¬í•©ë‹ˆë‹�. 나스ë‹� ìƒìž¥ ìžê²© 담당 ì§ì›ì€ SNSEì� 보통주가 2025ë…� 6ì›� 17ì¼ë¶€í„� 7ì›� 1ì¼ê¹Œì§€ 10거래ì� ì—°ì†ìœ¼ë¡œ 최소 $1.00ì� 종가ë¥� 유지했다ê³� 확ì¸í–ˆìŠµë‹ˆë‹¤. ì´ì— ë”°ë¼ ì´ì „ì� 위반 통지ëŠ� 종료ë˜ì—ˆìœ¼ë©° ìƒìž¥ íì§€ 위협ë� 제거ë˜ì—ˆìŠµë‹ˆë‹�.

ì´ë²ˆ í•´ê²°ë¡� 단기 ìƒìž¥ 위험ì� 해소ë˜ê³ , ì§€ìˆ� í¬í•¨ ìžê²©ê³� êµ­ê°€ 거래ì†� ì§€ìœ„ì— ì—°ê³„ë� 기관 투ìžìž� 소유 요건ì� 회복ë˜ë©°, 유ë™ì„� 제약ì—� 대í•� 투ìžìž� 우려가 ê°ì†Œí•©ë‹ˆë‹�. 다만, 준ìˆ� 여부ëŠ� SNSEê°€ 주가ë¥� 기준ì„� ì´ìƒìœ¼ë¡œ 유지í•� ìˆ� 있는지ì—� 달려 있으ë©�, $1.00 ì´í•˜ë¡� ì§€ì†� 하ë½í•˜ë©´ 새로ìš� 통지가 발행ë� ìˆ� 있습니다. ì´ë²ˆ 제출 서류ì—는 새로ìš� ìš´ì˜ ë˜ëŠ” 재무 ë°ì´í„°ê°€ í¬í•¨ë˜ì–´ 있지 않으ë©� 회사ì� 기본 펀ë”멘털ì—ëŠ� 변화가 없습니다.

Sensei Biotherapeutics, Inc. (SNSE) a annoncé, via un formulaire 8-K, point 3.01, qu’elle a retrouvé sa conformité avec la règle 5550(a)(2) du Nasdaq, qui exige un prix minimum d’offre de 1,00 $ par action. Le personnel des qualifications du Nasdaq a confirmé que l’action ordinaire de SNSE a maintenu un cours de clôture d’au moins 1,00 $ pendant dix jours ouvrables consécutifs (du 17 juin au 1er juillet 2025). Par conséquent, l’avis de non-conformité précédent a été clos et la menace de radiation a été levée.

Cette résolution élimine le risque de radiation à court terme, rétablit l’éligibilité à l’inclusion dans les indices et les mandats de propriété institutionnelle liés au statut d’échange national, et réduit les inquiétudes des investisseurs concernant d’éventuelles contraintes de liquidité. Cependant, la conformité dépend de la capacité de SNSE à maintenir son cours au-dessus du seuil ; toute baisse prolongée en dessous de 1,00 $ pourrait entraîner un nouvel avis. Le dépôt ne contient aucune nouvelle donnée opérationnelle ou financière et ne modifie pas les fondamentaux sous-jacents de l’entreprise.

Sensei Biotherapeutics, Inc. (SNSE) gab über ein Formblatt 8-K, Punkt 3.01, bekannt, dass es die Einhaltepflicht der Nasdaq-Listing-Regel 5550(a)(2) wiedererlangt hat, die einen Mindestgebotspreis von $1,00 pro Aktie verlangt. Das Nasdaq-Listing-Qualifikationsteam bestätigte, dass die Stammaktie von SNSE für zehn aufeinanderfolgende Handelstage (17. Juni bis 1. Juli 2025) einen Schlusskurs von mindestens $1,00 aufwies. Infolgedessen wurde die vorherige Mängelmitteilung geschlossen und die Delisting-Gefahr beseitigt.

Diese Lösung beseitigt das kurzfristige Listenrisiko, stellt die Berechtigung für die Indexaufnahme und institutionelle Besitzvorgaben, die an den Status einer nationalen Börse gebunden sind, wieder her und verringert die Anlegerbedenken hinsichtlich möglicher Liquiditätsengpässe. Die Einhaltung hängt jedoch davon ab, dass SNSE den Aktienkurs über der Schwelle hält; ein anhaltender Rückgang unter $1,00 könnte eine neue Mitteilung auslösen. Die Einreichung enthält keine neuen operativen oder finanziellen Daten und ändert nicht die zugrunde liegenden Fundamentaldaten des Unternehmens.

Positive
  • Regained Nasdaq compliance under Rule 5550(a)(2), removing imminent delisting risk.
  • Improved liquidity and investor perception by maintaining national exchange status.
Negative
  • Share-price fragility remains; any fall below $1.00 could renew deficiency.
  • Event does not address operational fundamentals or cash needs.

Insights

TL;DR: Nasdaq closes delisting threat; liquidity and investor confidence improve, but price must stay above $1.

The lift of the bid-price deficiency is materially positive for SNSE as it removes a technical overhang that can suppress trading volumes and deter institutional holders. Retention of Nasdaq listing preserves access to capital markets and potential inclusion in small-cap indices. The event does not address core clinical or cash-runway challenges; share price stability remains the key variable. Overall, the action is modestly accretive to sentiment rather than fundamentals.

TL;DR: Compliance restored, governance risk lowered; vigilance required to prevent future bid-price breaches.

Regained compliance signals effective board oversight in resolving exchange deficiencies, minimizing reputational and governance risk. Continued adherence will require proactive investor-relations outreach and potential corporate actions (reverse split, capital raise) if market pressure resurfaces. No changes to control structure or reporting obligations were disclosed.

Sensei Biotherapeutics, Inc. (SNSE) ha annunciato, tramite un modulo 8-K, voce 3.01, di aver ripristinato la conformità con la Regola 5550(a)(2) del Nasdaq, che richiede un prezzo minimo di offerta di $1,00 per azione. Lo staff delle qualifiche di Nasdaq ha confermato che il prezzo di chiusura delle azioni ordinarie di SNSE è rimasto almeno a $1,00 per dieci giorni lavorativi consecutivi (dal 17 giugno al 1 luglio 2025). Di conseguenza, la precedente notifica di non conformità è stata chiusa e il rischio di esclusione dal listino è stato eliminato.

Questa risoluzione elimina il rischio di esclusione a breve termine, ripristina l’idoneità per l’inclusione negli indici e per i requisiti di proprietà istituzionale legati allo status di borsa nazionale, e riduce le preoccupazioni degli investitori riguardo a potenziali vincoli di liquidità. Tuttavia, la conformità dipende dalla capacità di SNSE di mantenere il prezzo delle azioni sopra la soglia; un calo prolungato sotto $1,00 potrebbe causare una nuova notifica. Il documento non contiene nuovi dati operativi o finanziari e non modifica i fondamentali dell’azienda.

Sensei Biotherapeutics, Inc. (SNSE) anunció, a través de un Formulario 8-K, ítem 3.01, que ha recuperado el cumplimiento con la Norma 5550(a)(2) del Nasdaq, que exige un precio mínimo de oferta de $1.00 por acción. El personal de calificaciones del Nasdaq confirmó que las acciones ordinarias de SNSE mantuvieron un precio de cierre de al menos $1.00 durante diez días hábiles consecutivos (del 17 de junio al 1 de julio de 2025). Como resultado, se cerró el aviso previo de incumplimiento y se eliminó la amenaza de exclusión de la lista.

Esta resolución elimina el riesgo de exclusión a corto plazo, restaura la elegibilidad para la inclusión en índices y los mandatos de propiedad institucional vinculados al estatus de bolsa nacional, y reduce la preocupación de los inversores sobre posibles restricciones de liquidez. Sin embargo, el cumplimiento depende de la capacidad de SNSE para mantener el precio de sus acciones por encima del umbral; cualquier caída sostenida por debajo de $1.00 podría desencadenar un nuevo aviso. La presentación no contiene nuevos datos operativos o financieros y no altera los fundamentos subyacentes de la empresa.

Sensei Biotherapeutics, Inc. (SNSE)ëŠ� 8-K ì–‘ì‹ì� 항목 3.01ì� 통해 나스ë‹� ìƒìž¥ 규칙 5550(a)(2) 준수를 회복했다ê³� 발표했습니다. ì� ê·œì¹™ì€ ì£¼ë‹¹ 최소 입찰가가 $1.00 ì´ìƒì´ì–´ì•� í•¨ì„ ìš”êµ¬í•©ë‹ˆë‹�. 나스ë‹� ìƒìž¥ ìžê²© 담당 ì§ì›ì€ SNSEì� 보통주가 2025ë…� 6ì›� 17ì¼ë¶€í„� 7ì›� 1ì¼ê¹Œì§€ 10거래ì� ì—°ì†ìœ¼ë¡œ 최소 $1.00ì� 종가ë¥� 유지했다ê³� 확ì¸í–ˆìŠµë‹ˆë‹¤. ì´ì— ë”°ë¼ ì´ì „ì� 위반 통지ëŠ� 종료ë˜ì—ˆìœ¼ë©° ìƒìž¥ íì§€ 위협ë� 제거ë˜ì—ˆìŠµë‹ˆë‹�.

ì´ë²ˆ í•´ê²°ë¡� 단기 ìƒìž¥ 위험ì� 해소ë˜ê³ , ì§€ìˆ� í¬í•¨ ìžê²©ê³� êµ­ê°€ 거래ì†� ì§€ìœ„ì— ì—°ê³„ë� 기관 투ìžìž� 소유 요건ì� 회복ë˜ë©°, 유ë™ì„� 제약ì—� 대í•� 투ìžìž� 우려가 ê°ì†Œí•©ë‹ˆë‹�. 다만, 준ìˆ� 여부ëŠ� SNSEê°€ 주가ë¥� 기준ì„� ì´ìƒìœ¼ë¡œ 유지í•� ìˆ� 있는지ì—� 달려 있으ë©�, $1.00 ì´í•˜ë¡� ì§€ì†� 하ë½í•˜ë©´ 새로ìš� 통지가 발행ë� ìˆ� 있습니다. ì´ë²ˆ 제출 서류ì—는 새로ìš� ìš´ì˜ ë˜ëŠ” 재무 ë°ì´í„°ê°€ í¬í•¨ë˜ì–´ 있지 않으ë©� 회사ì� 기본 펀ë”멘털ì—ëŠ� 변화가 없습니다.

Sensei Biotherapeutics, Inc. (SNSE) a annoncé, via un formulaire 8-K, point 3.01, qu’elle a retrouvé sa conformité avec la règle 5550(a)(2) du Nasdaq, qui exige un prix minimum d’offre de 1,00 $ par action. Le personnel des qualifications du Nasdaq a confirmé que l’action ordinaire de SNSE a maintenu un cours de clôture d’au moins 1,00 $ pendant dix jours ouvrables consécutifs (du 17 juin au 1er juillet 2025). Par conséquent, l’avis de non-conformité précédent a été clos et la menace de radiation a été levée.

Cette résolution élimine le risque de radiation à court terme, rétablit l’éligibilité à l’inclusion dans les indices et les mandats de propriété institutionnelle liés au statut d’échange national, et réduit les inquiétudes des investisseurs concernant d’éventuelles contraintes de liquidité. Cependant, la conformité dépend de la capacité de SNSE à maintenir son cours au-dessus du seuil ; toute baisse prolongée en dessous de 1,00 $ pourrait entraîner un nouvel avis. Le dépôt ne contient aucune nouvelle donnée opérationnelle ou financière et ne modifie pas les fondamentaux sous-jacents de l’entreprise.

Sensei Biotherapeutics, Inc. (SNSE) gab über ein Formblatt 8-K, Punkt 3.01, bekannt, dass es die Einhaltepflicht der Nasdaq-Listing-Regel 5550(a)(2) wiedererlangt hat, die einen Mindestgebotspreis von $1,00 pro Aktie verlangt. Das Nasdaq-Listing-Qualifikationsteam bestätigte, dass die Stammaktie von SNSE für zehn aufeinanderfolgende Handelstage (17. Juni bis 1. Juli 2025) einen Schlusskurs von mindestens $1,00 aufwies. Infolgedessen wurde die vorherige Mängelmitteilung geschlossen und die Delisting-Gefahr beseitigt.

Diese Lösung beseitigt das kurzfristige Listenrisiko, stellt die Berechtigung für die Indexaufnahme und institutionelle Besitzvorgaben, die an den Status einer nationalen Börse gebunden sind, wieder her und verringert die Anlegerbedenken hinsichtlich möglicher Liquiditätsengpässe. Die Einhaltung hängt jedoch davon ab, dass SNSE den Aktienkurs über der Schwelle hält; ein anhaltender Rückgang unter $1,00 könnte eine neue Mitteilung auslösen. Die Einreichung enthält keine neuen operativen oder finanziellen Daten und ändert nicht die zugrunde liegenden Fundamentaldaten des Unternehmens.

0001515673false00015156732025-07-092025-07-09

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 09, 2025

 

 

Ultragenyx Pharmaceutical Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36276

27-2546083

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

60 Leveroni Court

 

Novato, California

 

94949

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 415 483-8800

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

RARE

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


 

Item 8.01

Other Events.

On July 9, 2025, Ultragenyx Pharmaceutical Inc. (the “Company”) announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (“OI”) is progressing toward a final analysis consistent with the original plan, around the end of the year.

The Data Monitoring Committee (the “DMC”) met and informed the Company that UX143 demonstrates an acceptable safety profile and the Company should continue the study to the final analysis.

Consistent with the statistical analysis plan, data from the UX143 Cosmic study were not analyzed at this interim timepoint. Study conduct is going well and safety in this younger patient population is consistent with the safety profile in the other studies.

Patients will continue dosing in the ongoing Phase 3 Orbit and Cosmic clinical studies with the final analyses to be conducted after patients have been on therapy for at least 18 months. The threshold for the Phase 3 Orbit final analysis is p<0.04 and for the Phase 3 Cosmic final analysis is p<0.05.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, “anticipates,” “continue,” “will,” or other similar terms or expressions that concern the Company’s expectations, plans and intentions. Forward-looking statements include, without limitation, statements regarding the clinical benefit, tolerability and safety of UX143, the Company’s expectations and projections regarding its future operating results and financial performance, business plans and objectives for UX143, and future clinical and regulatory developments for UX143, including the timing of the final analysis of the Phase 3 studies for UX143 and the outcomes from such studies. Such forward-looking statements involve substantial risks and uncertainties including, among others, the uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals, the ability of the Company to successfully develop UX143, the Company’s ability to achieve its projected development goals in its expected timeframes, the risk that results from earlier studies may not be predictive of future study results, risks related to adverse side effects, risks related to reliance on third party partners to conduct certain activities on the Company’s behalf, smaller than anticipated market opportunities for the Company’s products and product candidates, manufacturing risks, competition from other therapies or products, and other matters that could affect the sufficiency of existing cash, cash equivalents and short-term investments to fund operations, the Company’s future operating results and financial performance, the timing of clinical trial activities and reporting results from same, and the availability or commercial potential of the Company’s products and drug candidates. The Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 7, 2025, and its subsequent periodic reports filed with the SEC.

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Ultragenyx Pharmaceutical Inc.

 

 

 

 

Date:

July 9, 2025

By:

/s/ Howard Horn

 

 

 

Howard Horn
Executive Vice President, Chief Financial Officer, Corporate Strategy

 

 


FAQ

Why did Sensei Biotherapeutics (SNSE) file this Form 8-K?

To disclose that Nasdaq confirmed SNSE has regained compliance with the $1.00 minimum bid-price rule.

What is Nasdaq Listing Rule 5550(a)(2)?

It requires a company’s common stock to maintain a minimum closing bid price of $1.00 for continued listing on the Nasdaq Capital Market.

How did SNSE regain compliance?

SNSE’s shares closed at or above $1.00 for 10 consecutive business days (17 Junâ€�1 Jul 2025), satisfying Nasdaq’s cure criteria.

Does this filing affect SNSE’s financial outlook?

No financial metrics were disclosed; the filing solely addresses listing status, not operational performance.

Could SNSE face delisting again?

Yes. If the bid price falls below $1.00 for 30 consecutive business days, Nasdaq may issue a new deficiency notice.
Ultragenyx Pharm

NASDAQ:RARE

RARE Rankings

RARE Latest News

RARE Latest SEC Filings

RARE Stock Data

3.43B
90.51M
3.65%
98.31%
4.96%
Biotechnology
Pharmaceutical Preparations
United States
NOVATO